Top Page
Collplant Holdings
(NASDAQ:CLGN)
Collplant Holdings (CLGN) vs. SPDR S&P 500 ETF (SPY)
Collplant Holdings Business Overview & Revenue Model
Collplant Holdings Earnings Call Summary
Collplant Holdings Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.48M | 515.00K | 10.96M | 299.00K | 15.64M | 6.14M |
| Gross Profit | 622.00K | -2.15M | 7.87M | -1.18M | 13.64M | 2.68M |
| EBITDA | -11.05M | -15.55M | -5.91M | -15.81M | 1.05M | -5.08M |
| Net Income | -12.16M | -16.61M | -7.02M | -16.93M | 237.00K | -5.77M |
Balance Sheet | ||||||
| Total Assets | 14.09M | 18.71M | 34.13M | 37.77M | 51.22M | 10.84M |
| Cash, Cash Equivalents and Short-Term Investments | 8.55M | 11.91M | 26.67M | 29.65M | 43.30M | 3.33M |
| Total Debt | 2.94M | 3.08M | 3.16M | 2.91M | 3.61M | 3.39M |
| Total Liabilities | 4.78M | 5.25M | 5.79M | 5.49M | 6.10M | 6.36M |
| Stockholders Equity | 9.30M | 13.46M | 28.34M | 32.28M | 45.12M | 4.48M |
Cash Flow | ||||||
| Free Cash Flow | -10.02M | -14.58M | -3.72M | -14.97M | 1.07M | -4.89M |
| Operating Cash Flow | -9.95M | -14.09M | -2.76M | -13.70M | 2.50M | -4.45M |
| Investing Cash Flow | -70.00K | -539.00K | -1.16M | 28.92M | -31.56M | -519.00K |
| Financing Cash Flow | 3.10M | 9.00K | 1.11M | 1.87M | 38.76M | 4.46M |
Collplant Holdings Technical Analysis
Collplant Holdings Risk Analysis
Collplant Holdings Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $33.84M | -0.81 | -21.16% | ― | -92.42% | 62.37% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | $24.14M | ― | -87.18% | ― | ― | 38.42% | |
41 Neutral | $62.63M | ― | -390.53% | ― | ― | 61.23% | |
40 Neutral | $28.36M | ― | -92.74% | ― | 280.77% | 32.82% | |
38 Underperform | $24.40M | -4.10 | ― | ― | ― | ― | |
30 Underperform | $25.59M | -1.78 | ― | ― | ― | 31.09% |
Collplant Holdings Corporate Events
On November 26, 2025, CollPlant Biotechnologies Ltd. announced that it will hold its annual and extraordinary general meeting of shareholders on December 31, 2025, in Tel-Aviv, Israel. The meeting will address several key proposals, including the re-election of board members, re-appointment of auditors, renewal of the compensation policy for directors and officers, and the appointment of CEO Yehiel Tal as interim Chairman of the Board. The outcomes of this meeting could influence the company’s governance and strategic direction, impacting stakeholders and potentially affecting its market position.
CollPlant Biotechnologies reported its third-quarter financial results for 2025, highlighting significant advancements and strategic initiatives. The company announced the expansion of its rhCollagen and BioInk sales in North America through a new logistics partnership and commercial leadership, aiming to enhance its market presence. Recent developments include a collaboration with Mayo Clinic to create a humanized bioprinted skin model, and a comparative study showing its bioink, Collink.3D™, outperformed a leading extracellular matrix in tissue formation. Additionally, CollPlant is implementing cost-reduction measures and prioritizing its collaboration with AbbVie and the development of its dermal filler product. The company is also expanding its international distribution network for its tendon-repair product, Vergenix™ STR, into new markets.
On October 27, 2025, CollPlant Biotechnologies announced the expansion of its distribution capabilities in North America through a new partnership with a U.S.-based logistics center. This new logistics hub, which is set to become operational within the quarter, will enhance the distribution of CollPlant’s rhCollagen and BioInk products in the U.S. and Canada. The center is equipped with advanced infrastructure to ensure efficient and secure distribution, reflecting CollPlant’s commitment to the North American market and its strategy to improve logistical efficiency and customer service.
On October 20, 2025, CollPlant Biotechnologies announced positive results from a study conducted by the Technion – Israel Institute of Technology, which demonstrated that its rhCollagen-based bioink, Collink.3D™, outperformed Matrigel® in supporting structured tissue formation. This suggests that Collink.3D™ could serve as a next-generation, animal-free extracellular matrix for advanced tissue engineering and research applications, potentially impacting the market for basement membrane matrices, which is projected to grow significantly by 2031.
On October 16, 2025, CollPlant Biotechnologies announced the development of a first-of-its-kind fully humanized 3D bioprinted human skin model by Mayo Clinic researchers, utilizing CollPlant’s rhCollagen-based bioink. This model, which serves as an alternative to animal testing, has significant implications for cosmetic and pharmaceutical testing, disease modeling, and drug development, offering a sustainable and ethical solution while advancing regenerative medicine.
On September 30, 2025, CollPlant Biotechnologies announced positive results from non-clinical studies of its photocurable regenerative dermal and soft tissue filler. This product, which combines hyaluronic acid with a modified form of rhCollagen, is designed to offer both immediate and long-lasting benefits in aesthetic medicine. The successful completion of these studies marks a significant milestone for CollPlant as it prepares to advance the filler into clinical trials, potentially redefining standards in aesthetic treatments by integrating contouring precision, structural support, and tissue regeneration.
On September 15, 2025, CollPlant Biotechnologies announced the expansion of its European distribution network for its VergenixSTR product by signing a new agreement in Poland. VergenixSTR, a soft tissue repair matrix designed to treat tendinopathy, combines rhCollagen with platelet-rich plasma to promote tendon healing. This expansion is part of CollPlant’s strategy to broaden its global distribution network, enhancing its market presence in Europe and the Asia-Pacific region.
CollPlant Biotechnologies Ltd. announced that it has successfully transferred the listing of its ordinary shares from the Nasdaq Global Market to the Nasdaq Capital Market, effective September 12, 2025. This move is part of the company’s strategic efforts to optimize its market positioning while maintaining the trading symbol ‘CLGN’. The transfer is expected to have no impact on the trading of its shares, ensuring continuity for investors and stakeholders.